Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Non-Current Assets (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other Non-Current Assets for 14 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 34.12% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 34.12% year-over-year, with the annual reading at $5.6 million for FY2025, 34.12% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $5.6 million at Myriad Genetics, down from $6.6 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $22.1 million in Q2 2023, with the low at $3.6 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $10.7 million, with a median of $8.4 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets surged 566.67% in 2021, then tumbled 60.0% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $8.3 million in 2021, then skyrocketed by 86.75% to $15.5 million in 2022, then fell by 0.65% to $15.4 million in 2023, then plummeted by 44.81% to $8.5 million in 2024, then tumbled by 34.12% to $5.6 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $5.6 million, $6.6 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.